A Cochrane review [Abstract] 1 included 8 studies with a total of 1366 subjects with confirmed Huntington's disease. The median duration of studies was 52 weeks. The selected interventions were vitamin E, idebenone, baclofen, lamotrigine, creatine, coenzyme Q10 + remacemide, ethyl-eicosapentanoic acid and riluzole. The most frequently used primary outcome measure was a change in functional capacity using the Total Function Capacity (TFC)-UHDRS. No intervention produced positive results for the selected efficacy outcome measures. The selected interventions were found to be generally safe and well tolerated.
Comment: The quality of evidence is downgraded by study limitations (inadequate allocation concealment), inconsistency (heterogeneity in interventions and outcomes) and indirectness of evidence (differences between the population).
Primary/Secondary Keywords